FLECAINIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H20F6N2O3
Molecular Weight	414.3434
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1CCNC(C1)CN=C(c2cc(ccc2OCC(F)(F)F)OCC(F)(F)F)O

InChI

InChIKey=DJBNUMBKLMJRSA-UHFFFAOYSA-N

InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB01195
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/flecainide.html

Flecainide is a potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Sodium channel protein type V alpha subunit 47 Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21194571	Inhibitor 7701	67.2 µM [IC50]
Sodium channel protein type IV alpha subunit 21 Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20590641	Inhibitor 7701	18.0 µM [Ki]
HERG 90 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26159617	Inhibitor 7701	1.49 µM [IC50]
Voltage-gated potassium channel subunit Kv4.3 7 Target ID: CHEMBL1964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12875427	Inhibitor 7701	7.8 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Paroxysmal atrial fibrillation 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 7997	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 9.9645122E11
Documented ventricular arrhythmias 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 7997	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 9.9645122E11

C_max

Value	Dose	Co-administered	Analyte	Population
355 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1710 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
5979 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6238 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.9 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
60% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6364769			FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	Disc. AE: Unconsciousness, Cyanosis... AEs leading to discontinuation/dose reduction: Unconsciousness Cyanosis Bradycardia Arrhythmia Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Co-administed with:: diazepam, p.o(50 mg) loperamide, p.o(20 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	Disc. AE: Polymorphic ventricular tachycardia... AEs leading to discontinuation/dose reduction: Polymorphic ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	Disc. AE: Ventricular tachycardia, Hypotension... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Hypotension Cardiopulmonary arrest Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	Disc. AE: Brugada syndrome, Mental status changes... AEs leading to discontinuation/dose reduction: Brugada syndrome Mental status changes Fatigue Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Condition: Paroxysmal supraventricular tachycardias\|paroxysmal atrial fibrillation/flutter\|Sustained ventricular tachycardia Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	Disc. AE: Ventricular tachycardia, Cardiac arrest... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Cardiac arrest Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

AEs

AE	Significance	Dose	Population
Arrhythmia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Bradycardia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Cyanosis	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Unconsciousness	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Polymorphic ventricular tachycardia	Disc. AE	3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Co-administed with:: diazepam, p.o(50 mg) loperamide, p.o(20 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
Cardiopulmonary arrest	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
Hypotension	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
Ventricular tachycardia	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
Brugada syndrome	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
Fatigue	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
Mental status changes	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
Cardiac arrest	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Condition: Paroxysmal supraventricular tachycardias\|paroxysmal atrial fibrillation/flutter\|Sustained ventricular tachycardia Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Ventricular tachycardia	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Condition: Paroxysmal supraventricular tachycardias\|paroxysmal atrial fibrillation/flutter\|Sustained ventricular tachycardia Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1318	substrate 1038 inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 582	CYP1A2 892

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1455	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.44 uM]
CYP2C9 1362	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.49 uM]
OCT2 583	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 191 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 892	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes
CYP2D6 1038	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes		yes (co-administration study) Comment: During the period in which the CYP2D6 inhibitor paroxetine was administered, the flecainide AUC in extensive and intermediate metabolizers was increased to 128.5% of basal values (90% CI, 122.2%– 135.2%) and 116.6% of basal values (90% CI, 107.3%–126.8%). However, poor metabolizers exhibited no alterations in AUC after administration of paroxetine (pharmacogenomic studies were also performed) Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573407/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:75984	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75984
ChemicalBook	CB0663265	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0663265
MolPort	MolPort-003-847-380	https://www.molport.com/shop/molecule-link/MolPort-003-847-380
eMolecules	901891	https://www.emolecules.com/cgi-bin/more?vid=901891

PubMed

Title	Date	PubMed
Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.	1986 Dec	3105568
Dysarthria and visual hallucinations due to flecainide toxicity.	1986 Jan	3099275
Rapid suppression of flecainide-induced incessant ventricular tachycardia with high-dose intravenous amiodarone.	1988 Apr	3127126
[Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide].	1988 Mar 11	3127189
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.	1989 Dec	2513143
Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.	1989 Dec	2480856
Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.	1989 Jul 15	2500880
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium].	1989 Sep	2510412
Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.	1990 Aug 1	2114784
Acute urinary retention associated with flecainide.	1990 Jan-Feb	2106405
[Effects of oral flecainide treatment of refractory tachyarrhythmias].	1990 May	2115193
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.	1991 Aug	1906902
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.	1991 Dec 15	1720917
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.	1991 Mar 21	1900101
Proarrhythmic and antiarrhythmic effects of flecainide on nonsustained reentry around the canine atrial tricuspid ring in vitro.	1991 Nov	1721165
Flecainide in quinidine-resistant atrial fibrillation.	1992 Aug 20	1510001
Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators.	1992 Aug 20	1509993
Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide.	1992 Aug 29	1354292
Pseudo infarction ECG pattern occurring during intravenous treatment with flecainide acetate.	1992 Jan	1577021
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.	1992 Jul	1607582
Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.	1992 Oct	1449923
Flecainide induced peripheral neuropathy.	1992 Oct 3	1330141
A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation.	1992 Sep	1514492
Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.	2002 Apr	11932086
Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro.	2003 Aug	12730611
Flecainide test in Brugada syndrome: a reproducible but risky tool.	2003 Jan	12687841
Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.	2003 Jun 15	12804730
Flecainide induced ventricular fibrillation in a neonate.	2003 Oct	12975443
Flecainide induced ventricular tachycardia (torsades de pointes).	2003 Sep	12930510
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.	2004 Jul	15272206
Brugada pattern electrocardiographic changes associated with profound electrolyte disturbance.	2004 Jul	15271030
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.	2004 Nov	15546305
Electrocardiographical case. Asymptomatic patient with ST-segment elevation.	2004 Nov	15510328
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.	2005 Feb	15342952
[Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].	2006 May	16805213
Management of atrial fibrillation.	2007	17583181
[Clinical case of the month. Atrial flutter with rapid ventricular response (1:1 atrioventricular conduction) caused by flecaïnide].	2007 Dec	18286943
Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.	2007 Mar	17175557
[Sinus caroticus syndrome diagnosed after 43 years].	2007 Nov 12	18078652
The use of bupropion SR in cigarette smoking cessation.	2008	18488428
Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.	2008	18376118
Drug therapy considerations in arrhythmias in children.	2008 Aug 1	18679519
Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel.	2008 Aug 15	18599870
Ventricular dysfunction: tachycardia induced cardiomyopathy.	2008 May 1	18478066
Role of cytochrome P450 in drug interactions.	2008 Oct 18	18928560
Is flecainide dangerous in long QT-3 patients?	2009 Jan	19140927
Iatrogenic Flecainide toxicity.	2010 Dec	20736205
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.	2010 Feb	19897501
Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.	2011 Oct	21515356
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.	2013 Dec	24052561

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Ventricular Tachycardia Initial dose: 100 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved. Most patients with SUSTAINED VT do not require more than 150 mg every 12 hours (300 mg/day), and the maximum dose recommended is 400 mg/day. Usual Adult Dose for Atrial Fibrillation Initial dose: 50 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved.

Route of Administration: Oral

In Vitro Use Guide

Flecainide produced a dose-dependent prolongation of the cardiac action potential at 1 and 3uM in human pluripotent stem cell-derived cardiomyocytes.

Name

Type

Language

FLECAINIDE

Official Name

English

N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE

Systematic Name

English

FLECAINIDE [VANDF]

Common Name

English

THN102 COMPONENT FLECAINIDE

Common Name

English

THN-102 COMPONENT FLECAINIDE

Code

English

FLECAINIDE [MI]

Common Name

English

FLECAINIDE [WHO-DD]

Common Name

English

NSC-719273

Code

English

FLECAINIDE [INN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175426